GPX4 and lung carcinoma: GPX4 is upregulated in many patients with lung cancers and causes resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), radiotherapy, and immune checkpoint inhibitors [15].